NCT03333616View on ClinicalTrials.gov

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 28, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Genitourinary CancerAdrenocortical CarcinomaNon-urothelial BladderNon-urothelial Upper TractPenile CancerNon-adenocarcinoma Prostate CancerRefractory Germ-cellHigh Grade Neuroendocrine Carcinoma/Small Cell Carcinoma
Interventions
DRUG

Ipilimumab

is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.

DRUG

Nivolumab

Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells

Trial Locations (6)

30322

Winship Cancer Institute, Emory University, Atlanta

43210

Ohio State University Comprehensive Cancer Center, Columbus

77030

MD Anderson Cancer Center, Houston

92093

University of California, San Diego Moores Cancer Center, La Jolla

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER